Références Annexes

  1. World Health Organization. Rapid implementation of the Xpert MTB/RIF diagnostic test [Internet]. Geneva; 2011

  2. Giusti, G. (1974). Adenosine deaminase. In Bergmeyer, H.U. (ed). Method of enzymatic analysis, Vol. II VCH Weinheim. Florida. P1072 . Rajesh Baheti, Purnima Ladha, RS Gehlot Indian Academy of Clinical Medicine. Vol.2(4): 285-287; Oct. Dec. 2001[12]

  3. Burgess LJ, Maritz FJ, Le Roux I, Taljaard JJ. Combined use of pleural adenosine deaminase with lymphocyte/neutrophil ratio. Increased specificity for the diagnosis of tuberculous pleuritis. Chest 1996; 109:414.

  4. Riquelme A, Calvo M, Salech F, et al. Value of adenosine deaminase (ADA) in ascitic fluid for the diagnosis of tuberculous peritonitis: a meta-analysis. J Clin Gastroenterol 2006; 40:705.

  5. PIH Guide on the Medical management of MDR-TB, Partners In Health, Boston. 2003

  6. Francis J. Curry National Tuberculosis Center and California Department of Public Health, 2008: Drug-Resistant Tuberculosis: A Survival Guide for Clinicians, Second Edition.

  7. Centers for Disease Control and Prevention, American Thoracic Society, Infectious Diseases Society of America. Treatment of tuberculosis. Morbidity and Mortality Weekly Report, 2003, 52(RR11):1–77.

  8. Organisation mondiale de la Santé. Principes directeurs à l'intention des programmes antituberculeux pour la prise en charge des tuberculoses pharmacorésistantes. Mise à jour 2008. (WHO/HTM/TB/2008.402).

  9. I Coker, E Nardell, B Fourie, P Brickner, S Parsons, N Bhagwandin and P Onyebujoh. Guidelines for the Utilisation of Ultraviolet Germicidal Irradiation technology in controlling transmission of tuberculosis in health care facilities in South Africa. MRC.

  10. Xu P. Ultraviolet germicidal irradiation for preventing infectious disease transmission. Boulder, CO: University of Colorado, Department of Civil, Environmental, and Architectural Engineering; 2001.

  11. Collins FM. Relative susceptibility of acid-fast and non-acid-fast bacteria to ultraviolet light. Appl Microbiol 1971;21:411–3.

  12. Kethley TW, Branch K. Ultraviolet lamps for room air disinfection. Effect of sampling location and particle size of bacterial aerosol. Arc Environ Health 1972;25:205–14.

  13. Riley RL, Permutt S. Room air disinfection by ultraviolet irradiation of upper air. Air mixing and germicidal effectiveness. Arch Environ Health 1971;22:208–19.

  14. Riley RL, Kaufman JE. Air disinfection in corridors by upper air irradiation with ultraviolet. Arch Environ Health 1971;22:551–3.

  15. Ko G, First MW, Burge HA. The characterization of upper-room ultraviolet germicidal irradiation in inactivating airborne microorganisms. Environmental Health Perspectives 2002;110:95–101.

  16. Ko G, First MW, Burge HA. Influence of relative humidity on particle size and UV sensitivity of Serratia marcescens and Mycobacterium bovis BCG aerosols. Tubercle Lung Dis 2000;80:217–28.

  17. Peccia J, Werth HM, Miller S, Hernandez M. Effects of relative humidity on the ultraviolet induced inactivation of airborne bacteria. Aerosol Science and Technology 2001;35:728–40.

  18. Riley RL, Kaufman JE. Effect of relative humidity on the inactivation of airborne Serratia marcescens by ultraviolet radiation. Appl Microbiol 1972;23:1113–20.

  19. First MW, Nardell EA, Chaisson W, Riley R. Guidelines for the application of upper-room ultraviolet germicidal irradiation for preventing transmission of airborne contagion—part I: basic principles. ASHRAE Trans 1999:105:869–876.

  20. Riley RL, Nardell EA [1989]. Clearing the air: the theory and application of ultraviolet air disinfection. Am Rev Respir Dis 139(5):1286–1294.

  21. WHO. Policy on TB Infection Control, 2009.

  22. Fallo A, Torrado L, Sánchez A, Cerqueiro C, Schargrodsky L, López EL. Delayed complications of Bacillus Calmette-Guérin (BCG) vaccination in HIV-infected children. In: International AIDS Society Conference, Rio de Janeiro, 24–27 July 2005.

  23. Hesseling AC, Marais BJ, Gie RP, Schaaf HS, Fine PEM, et al., et al. The risk of disseminated Bacille Calmette-Guérin (BCG) disease in HIV-infected children. Vaccine 2007; 25: 14-8 doi: 10.1016/j.vaccine.2006.07.020 pmid:16959383.

  24. Hesseling AC, Rabie H, Marais BJ, Manders M, Lips M, Schaaf HS, et al., et al. Bacille Calmette-Guérin vaccine-induced disease in HIV-infected and HIV-uninfected children. Clin Infect Dis 2006; 42: 548-58 doi: 10.1086/499953pmid: 16421800.